Related references
Note: Only part of the references are listed.Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone
Thomas Danne et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2021)
6. Glycemic Targets: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study
Torben Biester et al.
DIABETES OBESITY & METABOLISM (2021)
The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes
Peter Gerhardsson et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2021)
Effect of an Integrated, Multidisciplinary Nationwide Approach to Type 1 Diabetes Care on Metabolic Outcomes: An Observational Real-World Study
Astrid Lavens et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2021)
Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes
Daniel H. van Raalte et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II
Timothy M. E. Davis et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial
Chantal Mathieu et al.
DIABETES OBESITY & METABOLISM (2020)
Benefit/risk profile of dapagliflozin 5 mg in theDEPICT-1 and-2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2
Chantal Mathieu et al.
DIABETES OBESITY & METABOLISM (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
Per-Henrik Groop et al.
Lancet Diabetes & Endocrinology (2020)
Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement
Ajitesh Roy et al.
DIABETES THERAPY (2020)
SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
Birgit Janssens et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2020)
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors
Thomas Danne et al.
DIABETES CARE (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018
Nicole C. Foster et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25year period 1989-2013: a multicentre prospective registration study
Christopher C. Patterson et al.
DIABETOLOGIA (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
Simeon I. Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
HbA(1c) and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
Thomas Danne et al.
DIABETES CARE (2018)
SGLT inhibitor adjunct therapy in type 1 diabetes
Rory J. McCrimmon et al.
DIABETOLOGIA (2018)
Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
Satish K. Garg et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
Paresh Dandona et al.
DIABETES CARE (2018)
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Julio Rosenstock et al.
DIABETES CARE (2018)
Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: study protocol for a randomised controlled trial
Susanne Amsberg et al.
BMJ OPEN (2018)
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes
Helena W. Rodbard et al.
DIABETES CARE (2017)
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Satish K. Garg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome
Erik J. M. van Bommel et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Current State of Type 1 Diabetes Treatment in the US: Updated Data From the T1D Exchange Clinic Registry
Kellee M. Miller et al.
DIABETES CARE (2015)
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
David M. Nathan
DIABETES CARE (2014)
Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry
Ruth S. Weinstock et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Temporal patterns in overweight and obesity in Type 1 diabetes
B. Conway et al.
DIABETIC MEDICINE (2010)
Share Paper
